Navigation Links
Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors
Date:5/21/2013

NORTH BRUNSWICK, N.J., May 21, 2013 /PRNewswire/ -- Hurel Corporation ("Hurel"), a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms, today announced the appointment of James S. MacDonald , PhD, DABT to the Company's Board of Directors. Dr. MacDonald is the former Executive Vice President of Preclinical Development of the Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical development arm of Schering Corporation prior to its acquisition by Merck & Co. in 2009.

Over a career that has spanned more than three decades, Dr. MacDonald has brought hundreds of drug candidates into development, over thirty of which have become globally registered, major drugs, including Vasotec®, Zocor®, Primaxin®, Clinoril®, Prilosec®, Fosamax®, Clarinex®, Nasonex®, Vytorin®, and Victrelis®, among others. Dr. MacDonald joined SPRI in 1994 as Senior Vice President, Drug Safety and Metabolism, and, over the next 14 years up until the time of the Merck acquisition, he played a leading role in building one of the most distinguished and effective drug development organizations in the world. As co-chairman of SPRI's Early Development Committee, he directed the movement of drug candidates from discovery research into and through the development process. Previously, Dr. MacDonald held positions of increasing responsibility at Merck, including Executive Director of Toxicology. He received his Ph.D. in toxicology in 1975 from the University of Cincinnati and completed a post-doctoral fellowship at Vanderbilt University. He became a diplomate of the American Board of Toxicology in 1980.

" Jim MacDonald 's track record of getting pharmaceuticals approved by FDA and onto the market speaks for itself," said Robert Freedman , Hµrel's Chairman and CEO. "Hµrel is privileged to benefit from Jim's extraordinary wisdom and experience, both as a scientist and as a drug development executive. His guidance will be invaluable. We welcome Jim to the Board as a colleague and friend."

About Hurel
Hurel Corporation, based in North Brunswick, NJ and Beverly Hills, CA, is a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms which are used by biotech and pharmaceutical research organizations in pre-clinical drug development, as well as in the toxicological testing of industrial materials and consumer products. The Company recently announced a $9.2 million Series "A" equity private placement led by Spring Mountain Capital, of New York.  Funds from the transaction will provide working capital to support the current commercial launch of the Company's products and the continuing research and development of its technologies and future products.


'/>"/>
SOURCE Hurel Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hurel Receives $9.2 Million Series A Funding From Spring Mountain Capital
2. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
3. X-Change Corporation Launches Upgraded Version of Phytiva Website, As Company Targets Distribution of Phytiva Product Line in United States and Worldwide, Extracts and New Products in Europe
4. Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan
5. Healthcare Corporation of America Sets Date for Release of its First-Quarter Results and Conference Call
6. Comprehensive Care Corporation Announces Pharmacy Savings Management Agreement With Utica City School District
7. Omeros Corporation Reports First Quarter 2013 Financial Results
8. Heska Corporation to Present at the 14th Annual B. Riley & Co. Investor Conference
9. Sigma-Aldrich Corporation Declares $0.215 Per Share Quarterly Dividend
10. Luminex Corporation To Present At Upcoming Investment Conferences
11. Celladon Corporation is a Finalist for the 2013 Red Herring Top 100 North America Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today ... Inc.,s Supplier Horizon Award . One ... Guerbet was recognized for its support of Premier members ... through clinical excellence, and commitment to lower costs. ... receive this recognition of our outstanding customer service from ...
Breaking Medicine Technology:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
Breaking Medicine News(10 mins):